US009410137B2

(12) **United States Patent**
Camire

(10) **Patent No.: US 9,410,137 B2**
(45) **Date of Patent: Aug. 9, 2016**

(54) **COMPOSITIONS AND METHODS FOR MODULATING HEMOSTASIS**

(71) Applicant: **The Children's Hospital of Philadelphia**, Philadelphia, PA (US)

(72) Inventor: **Rodney M. Camire**, Sicklerville, NJ (US)

(73) Assignee: **The Children's Hospital of Philadelphia**, Philadelphia, PA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 482 days.

(21) Appl. No.: **13/726,187**

(22) Filed: **Dec. 23, 2012**

(65) **Prior Publication Data**

US 2014/0120155 A1 May 1, 2014

Related U.S. Application Data

(62) Division of application No. 12/093,783, filed as application No. PCT/US2006/060927 on Nov. 15, 2006, now Pat. No. 8,383,386.

(60) Provisional application No. 60/736,680, filed on Nov. 15, 2005.

(51) **Int. Cl.**
C12N 9/64 (2006.01)
A61K 38/48 (2006.01)

(52) **U.S. Cl.**
CPC ***C12N 9/6432*** (2013.01); ***A61K 38/4846*** (2013.01); ***C12N 9/647*** (2013.01); ***C12Y 304/21006*** (2013.01)

(58) **Field of Classification Search**
CPC C12Y 304/21006; C12N 9/6432; A61K 38/4846
USPC 435/212; 530/384
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

6,958,322	B1	10/2005	Himmelspach et al.	
7,220,569	B2	5/2007	Himmelspach et al.	
8,436,144	B2 *	5/2013	Christophe et al.	530/381
2003/0181381	A1	9/2003	Himmelspach et al.	

FOREIGN PATENT DOCUMENTS

EP	1728798		12/2006	
WO	98/38317		9/1998	
WO	98/38318		9/1998	
WO	01/70763		9/2001	
WO	WO 03/035861	*	5/2003	C12N 9/64
WO	2004/005347		1/2004	

OTHER PUBLICATIONS

Maekawa et al, Biochemistry 32:6146-6151, 1993.*
Wolf, D.L., et al. "Design of Constructs for the Expression of Biologically Active Recombinant Human Factors X and Xa." J Biol Chem. Jul. 25, 1991;266(21)13726-13730.
Friedrich, R., et al. "Staphylocoagulase is a prototype for the mechanism of cofactor0induced zymogen activation." Nature, 425: 535-539 (Oct. 2, 2003).
"SEQ ID No. 2 mi file" uploaded as partial result from PTO search file entitled "Sequence Search—20070801_095501_pct-us06-60—20070801_095501_pct-us06-60927-2-.mi" in order to demonstrate homology of claimed sequence to previously published sequence.
Sun, T., et al. "Vitamin K epoxide reductase significantly improves carboxylation in a cell line overexpressing factor X." Blood, 106(12):3811-3815 (Aug. 4, 2005).
Camire, R., et al. "Enhanced gamma-carboxylation of recombinant factor X using a chimeric construct containing the prothromcin propeptide." Biochemistry, 39(46): 14322-14329 (Nov. 21, 2000).
Camire, R. "Prothrombinase assembly and S1 site occupation restore the catalytic activity of FXa impaired by mutation at the sodium-binding site." Journal of Biological Chemistry, 277(40):37863-37870 (Oct. 4, 2002).
Hedstrom, L, et al. "Hydrophobic interactions control zymogen activation in the trypsin family of serine proteases." Biochemistry, 35(14): 4515-4523 [Abstract] (1996).
Toso, R., et al. "Factor VII mutant V154G models a zymogen-like form of factor Vila." The Biochemical Journal, 369 (3):563-471 (Feb. 1, 2003).
Toso, R., et al. "Factor VII variants as tools to study Factor Vlla salt bridge formation." Database Biosis. Biosciences, Information Service, Philadelphia, PA & Blood, 98(11):526a (Nov. 16, 2001) [Abstract].
Toso, R., et al. "Alteration of the factor X zymogen to protease transition provides evidence for allosteric linkage between the S1 and FVa binding sites." Blood, 106(11):13A (Nov. 16, 2005).
Toso, R., et al. "The conformational switch from the factor X zymogen to protease state mediates exosite expression and prothrombinase assembly." Journal of Biological Chemistry, 283(17):18627-18635 (Jul. 2008).
Strandberg, L., et al. "Variants of tissue-type plasminogen activator with substantially enhanced response and selectivity toward fibrin co-factors." J Biol Chem. Oct. 6, 1995;270(40):23444-9.
Sziegoleit. GenBank CAA74031.1; 1997.
Wells, J.A. "Additivity of mutational effects in proteins." Biochemistry. Sep. 18, 1990;29(37):8509-17.
Ngo, J.T., et al. "Computational Complexity, Protein Structure Prediction and the Levinthal Paradox." In Peptide Hormones (J.A. Parsons, ed.) University Park Press. 1994:492-495.
Guo, H.H., et al. "Protein tolerance to random amino acid change." Proc Natl Acad Sci U S A. Jun. 22, 2004;101(25):9205-10. Epub Jun. 14, 2004.
Hult, K., et al. "Engineered enzymes for improved organic synthesis." Curr Opin Biotechnol. Aug. 2003;14(4):395-400.
Rudinger, J. "Characteristics of the amino acids as components of a peptide hormone sequence." In Peptide Hormones (J.A. Parsons, ed.) University Park Press.1976:1-7.
Holt, K. Q5JVE7, GI:74742424. May 2005.
Rudolph, A.E., et al. "Expression, purification, and characterization of recombinant human factor X." Protein Expr Purif. Aug. 1997;10(3):373-8.
Bianchini, E.P., et al. "Mapping of the catalytic groove preferences of factor Xa reveals an inadequate selectivity for its macromolecule substrates." J Biol Chem. Jun. 7, 2002;277(23):20527-34. Epub Mar. 29, 2002.
Khan, A.R., et al. "Molecular mechanisms for the conversion of zymogens to active proteolytic enzymes." Protein Science. 1998;7:815-836.

* cited by examiner

Primary Examiner — Kevin Hill
(74) *Attorney, Agent, or Firm* — Kathleen D. Rigaut; Dann, Dorfman, Herell & Skillman

(57) **ABSTRACT**

Factor Xa variants and methods of use thereof are disclosed.

20 Claims, 11 Drawing Sheets